Related Experiment Videos
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis
G Palladini1, E Anesi, V Perfetti
1Internal Medicine and Medical Oncology, and Biotechnology Research Laboratories, Policlinico San Matteo, Pavia, Italy.
British Journal of Haematology
|July 10, 2001
Summary
A modified, milder high-dose dexamethasone (HD-Dex) regimen showed a 35% response rate in AL amyloidosis patients. This less toxic approach may be suitable for front-line therapy when rapid response is crucial.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- High-dose dexamethasone (HD-Dex) is used for AL amyloidosis but can be toxic.
- The standard HD-Dex schedule showed significant toxicity during the induction phase in AL amyloidosis patients.
Purpose of the Study:
- To evaluate a modified, milder HD-Dex schedule for AL amyloidosis treatment.
- To assess the efficacy and toxicity of a reduced-dose dexamethasone regimen in AL amyloidosis.
Main Methods:
- A cohort of 23 AL amyloidosis patients received a modified HD-Dex schedule.
- Dexamethasone 40 mg was administered on days 1-4 every 21 days for up to eight cycles.
Main Results:
- Overall, 8 out of 23 (35%) patients responded to the modified HD-Dex regimen.
- The median time to response was 4 months (range 2-6 months).
- The modified regimen demonstrated minimal toxicity in treated patients.
Conclusions:
- A milder HD-Dex schedule is effective and less toxic for AL amyloidosis.
- This modified regimen can be considered for front-line therapy in AL amyloidosis when autologous stem cell transplantation is not feasible or rapid response is needed.